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Audits in clinical practice are in the air nowadays and the questions arising about the
prescription of hypolidemic agents are legion and all the more legitimate as the medical
expenses involved are considerable.
Even with its limits, correctly self-criticized in the discussion, CEPHEUS provides com-
plementary data that conﬁrm previous work that are less non-existent than the authors
claim [1—3].
The regression of ﬁbrates has pursued inexorably its course since the disappointing
results of the FIELD trial [4]. The level of proof of statins has restricted their indications
to severe and exclusive hypertriglyceridemia with vascular repercussions. Although the
place of rosuvastatin is certainly overestimated in this sample of general practitioners,
not necessarily representative, simvastatin has curiously remained in the background in
France. It has not been projected in the foreground as in Germany when it was converted
as generic.
The critical point converging with previous data remains the rate of attainment of the
objective which remains still low and the more so as the patients are high-risk patients.
This paradox is explainable only in part by a threshold to be reached that is even further
off. It is to be regretted that CEPHEUS study could not explore more deeply what concerns
the respective non-observance of the physician and the patient.
On the other hand, the merit of CEPHEUS is to have carefully examined the plasma
LDLc distribution. Indeed, to ﬁnd oneself at 50mg/l from the consensus threshold is not
necessarily catastrophic since the relation LDLc-CV risk is certainly not as linear in the
low values as some would like to believe. It is distressing to note that nearly 30% of the
high-risk patients retain a plasma LDLc concentration above 1.3 g/l and it is deplorable
that 1% retains an LDLc above 2 g/l while potent treatments are available.
 Assessment of lipid-lowering treatment in France —–The CEPHEUS study, Ferrières J, Tocque-Le Gousse E, Fabry C, Hermans MP,
on behalf of the French CEPHEUS Investigators, doi:10.1016/j.acvd.2008.08.006.
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Such observations open up avenues for industry to pro-
ote drug association and to develop new molecules.
evertheless, a rational use of existing resources consisting
n a systematic detection of high-risk patients and in titrat-
ng the most potent statins should allow one to compensate
his disparity in practice which is all the more reprehensible
s access to care is facilitated in France. Is wide statin dis-
ersion acceptable when the patients on the right side of the
auss Curve of the cardiovascular risk distribution are not
r inadequately treated?. . . Recruitment in the outpatients
linics of lipidology has shifted in the last 10 years since
e ﬁnd now only those who are intolerant to hypolipidemic
gents and those with major dyslipidemia resistant to con-
entional management. There is nowadays in each region at
east one tertiary care center for lipidology assessment and
t is deeply disappointing that this 1% of high-risk subjects
nefﬁciently treated remains not referred.
On the eve of the publication of JUPITER, a trial evalu-
ting rosuvatatin versus placebo in situation of increase in
ltra-sensitive CRP, thus in situation of metabolic syndrome,
t would have been useful to better deﬁne the modalities of
anagement of patients with a metabolic syndrome since
heir CV risk level is close to that of type 2 diabetics and thus
ake up a privileged target. Finally, CEPHEUS study pro-
ides conﬁrmation that a large proportion of patients under
reatment remains hypoalphalipoproteinemic. In spite of
[P. Moulin
he recent failure of torcetrapib [5], the development of
herapies able to simultaneously increase both HDLc level
nd cardiovascular beneﬁt remains henceforth a major chal-
enge for the coming 5 years.
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